证券代码：300676 证券简称：华大基因 公告编号：2025-010 深圳华大基因股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《深圳华大基因股份有限公司章程》（以 下简称《公司章程》）的有关规定，经深圳华大基因股份有限公司（以下简称公 司）第四届董事会第四次会议审议通过，公司董事会决定于2025年2月11日（星 期二）召开公司2025年第一次临时股东会。现就本次会议有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：深圳华大基因股份有限公司2025年第一次临时股东会 2、股东会召集人：公司董事会 3、会议召开的合法性及合规性：经公司第四届董事会第四次会议审议通过， 决定召开2025年第一次临时股东会，召集程序符合有关法律、行政法规、部门规 章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025年2月11日（星期二）14:30 （2）网络投票时间： ① 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年2 ...

证券代码：300676 证券简称：华大基因 公告编号：2025-007 深圳华大基因股份有限公司 关于 2025 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）2025 年度日常关联交易概述 1、深圳华大基因股份有限公司（以下简称华大基因或公司）根据公司业务 发展及日常经营的需要，预计 2025 年将与关联人发生的日常关联交易总金额不 超过 120,919 万元人民币（以下万元均指人民币万元），关联交易主要内容包括 采购商品或接受服务、销售商品或提供服务、向关联人出租或租赁及与关联人发 生的其他交易。其中，采购商品、接受服务的关联交易金额为 104,416 万元，销 售商品、提供服务的关联交易金额为 12,035 万元，其他类关联交易金额为 4,468 万元；2024 年度公司与关联人实际发生的日常关联交易总金额为 108,914 万元， 其中，采购类关联交易金额为 100,082 万元，销售类关联交易金额为 6,258 万元， 其他类关联交易金额为 2,574 万元（2024 年度数据未经审计）。 ...

Financial Performance Expectations - The company expects a net loss attributable to shareholders of approximately -75,000 to -92,000 million RMB for the year 2024, compared to a profit of 9,290 million RMB in the previous year[2] - Estimated operating revenue for 2024 is projected to be between 380,000 and 400,000 million RMB, representing a decline of approximately 8.04% to 12.64% year-over-year[4] - Non-recurring gains and losses are expected to impact net profit by approximately -2,000 to 3,000 million RMB, compared to 160,000 RMB in the previous year[6] Business Growth Projections - Revenue from routine testing business is expected to grow over 6% year-over-year, while tumor and chronic disease prevention business is anticipated to grow over 15%, with colorectal cancer testing revenue expected to exceed 200 million RMB, a year-over-year increase of approximately 272%[5] Profitability Challenges - The company has faced significant declines in gross margins for some products due to price reductions and product structure adjustments, impacting overall profitability[5] - Credit impairment losses are expected to increase significantly in 2024 due to extended customer payment cycles, prompting the company to enhance credit control measures[5] - The company has increased R&D investment to expand product lines and innovate key products, which has impacted net profit due to high R&D expenses amid stagnant revenue growth[5] - Increased depreciation and amortization expenses from recent investments in office, R&D, and production facilities have raised overall operating costs[6] Strategic Adjustments - The company is strategically reducing its global production centers to optimize resource allocation, leading to asset impairment provisions and temporary operating losses[5] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the 2024 annual report[7]

| | 是否为控股 | | | | | 是否为限 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 股东或第一 | | 本次质押数 | 占其所持 | 占公司 | 售股（如 | 是否为 | 质押起 | 质押到期 | | 质押用 | | 股东名称 | 大股东及其 | | 量（股） | 股份比例 | 总股本 | 是，注明 | 补充质 | 始日 | 日 | 质权人 | 途 | | | 一致行动人 | | | | 比例 | 限售类 | 押 | | | | | | | | | | | | 型） | | | | | | | | | | | | | | | | 至办理解 | 中国邮政 储蓄银行 | 自身生 | | 深圳华大 | | | | | | | | 2024/1 | 除质押登 | 股份有限 | 产经营 | | 基因科技 | | 是 | 7,700,000 | 5.18% | 1.85% | 否 | 否 | 2/27 | 记手续之 | 公司深圳 | 的资金 | | 有限公司 | | | | | ...

证券代码：300676 证券简称：华大基因 公告编号：2024-090 深圳华大基因股份有限公司 关于注销部分募集资金专户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意深圳华大基因股份有限公司向特定对 象发行股票注册的批复》（证监许可[2020]3580 号）同意，深圳华大基因股份有 限公司（以下简称公司）向特定对象发行人民币普通股（A 股）13,814,325 股， 募集资金总额为人民币 2,003,077,125.00 元，扣减不含税发行费用人民币 26,432,391.37 元，实际募集资金净额人民币 1,976,644,733.63 元。2021 年 1 月 27 日，公司的保荐机构中信证券股份有限公司（以下简称中信证券）将扣除承销及 保荐费后的募集资金余额划转至公司开立的募集资金专项账户（以下简称专户）。 以上募集资金到账情况已由安永华明会计师事务所（特殊普通合伙）于 2021 年 1 月 27 日出具的安永华明（2021）验字第 61098952_H02 号《验资报告》验证确 认。 ...

Group 1: Business Performance and Growth - The company's newborn genetic disease screening and genetic testing businesses achieved over 30% year-on-year growth [1][3] - The company increased its investment in chronic disease prevention for individuals aged 60 and above, particularly in cardiovascular disease [1][3] - Despite economic pressures, the company aims to maintain business growth and market share through strategic adjustments [2][4] Group 2: Strategic Adjustments and Market Response - The company is adjusting its global strategy due to declining business in North America and Europe, while experiencing significant growth in Southeast Asia and Latin America [2] - The company plans to enhance its product offerings and optimize its product matrix to meet diverse customer needs [3][4] - The company is focusing on improving asset utilization and reducing costs through automation and standardization [3] Group 3: Research and Development Initiatives - The company established an AI task force and launched the Generative Bio-Intelligent (GBI ALL) tool for intelligent interpretation of genetic disease diagnostics [1][3] - The company is actively pursuing new product development in the field of reproductive health management and prenatal diagnosis [4][5] - The company emphasizes innovation in molecular detection and has achieved significant patent results in various application areas [3] Group 4: Financial Challenges and Strategies - The company faced losses in the first three quarters of 2024 due to multiple factors, including economic downturn and decreased demand for testing [4] - The company is implementing strategic adjustments and organizational restructuring to improve efficiency and performance [4] - The company is committed to maintaining high R&D investment in core areas to ensure technological leadership [2][4]

Group 1 - The CRO concept stocks experienced a strong rebound, with WuXi AppTec hitting the daily limit and BGI Genomics rising over 2% [1] - U.S. lawmakers are considering changes to the Biosecure Act, which may include increased administrative review for related companies instead of an automatic ban on biopharmaceutical collaborations with Chinese firms [1] - BGI Genomics was specifically named in the U.S. Biosecure Act [3] Group 2 - The U.S. House of Representatives passed the Biosecure Act (H.R.8333) in September [2]

证券代码：300676 证券简称：华大基因 公告编号：2024-089 深圳华大基因股份有限公司 关于注销部分募集资金专户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意深圳华大基因股份有限公司向特定对 象发行股票注册的批复》（证监许可[2020]3580 号）同意，深圳华大基因股份有 限公司（以下简称公司）向特定对象发行人民币普通股（A 股）13,814,325 股， 募集资金总额为人民币 2,003,077,125.00 元，扣减不含税发行费用人民币 26,432,391.37 元，实际募集资金净额人民币 1,976,644,733.63 元。2021 年 1 月 27 日，公司的保荐机构中信证券股份有限公司（以下简称中信证券）将扣除承销及 保荐费后的募集资金余额划转至公司开立的募集资金专项账户（以下简称专户）。 以上募集资金到账情况已由安永华明会计师事务所（特殊普通合伙）于 2021 年 1 月 27 日出具的安永华明（2021）验字第 61098952_H02 号《验资报告》验证确 认。 ...